key: cord-1056546-jn827l26
authors: Akhand, Mst Rubaiat Nazneen; Azim, Kazi Faizul; Hoque, Syeda Farjana; Moli, Mahmuda Akther; Joy, Bijit Das; Akter, Hafsa; Afif, Ibrahim Khalil; Ahmed, Nadim; Hasan, Mahmudul
title: Genome based evolutionary lineage of SARS-CoV-2 towards the development of novel chimeric vaccine
date: 2020-09-01
journal: Infect Genet Evol
DOI: 10.1016/j.meegid.2020.104517
sha: 09fadc8dc91ec485b2309e93275d0d9a5c1203c5
doc_id: 1056546
cord_uid: jn827l26

The present study aimed to predict a novel chimeric vaccine by simultaneously targeting four major structural proteins via the establishment of ancestral relationship among different strains of coronaviruses. Conserved regions from the homologous protein sets of spike glycoprotein, membrane protein, envelope protein and nucleocapsid protein were identified through multiple sequence alignment. The phylogeny analyses of whole genome stated that four proteins reflected the close ancestral relation of SARS-CoV-2 to SARS-COV-1 and bat coronavirus. Numerous immunogenic epitopes (both T cell and B cell) were generated from the common fragments which were further ranked on the basis of antigenicity, transmembrane topology, conservancy level, toxicity and allergenicity pattern and population coverage analysis. Top putative epitopes were combined with appropriate adjuvants and linkers to construct a novel multiepitope subunit vaccine against COVID-19. The designed constructs were characterized based on physicochemical properties, allergenicity, antigenicity and solubility which revealed the superiority of construct V3 in terms safety and efficacy. Essential molecular dynamics and Normal Mode analysis confirmed minimal deformability of the refined model at molecular level. In addition, disulfide engineering was investigated to accelerate the stability of the protein. Molecular docking study ensured high binding affinity between construct V3 and HLA cells, as well as with different host receptors. Microbial expression and translational efficacy of the constructs were checked using pET28a(+) vector of E. coli strain K12. However, the in vivo and in vitro validation of suggested vaccine molecule might be ensured with wet lab trials using model animals for the implementation of the presented data.

protective immunity, whereas only a few numbers of proteins are necessary depending on the microbes (Tesh et al., 200, Li et al., 2014) . Depending on sufficient antigen expression from experimental assays, traditional vaccine could take 15 years to develop, while sometimes can lead to undesirable consequences (Purcell et al., 2007, Petrovsky and Aguilar, 2004) .

Reverse vaccinology approach, on the other hand, is an effective way to develop vaccine against COVID-19. In this method, computation analysis towards genomic architecture of pathogenic candidate could predict the antigens of pathogens without the prerequisite to culture the pathogens in lab condition. Although, few pathogens that challenge to develop effective vaccines so far may become possible through such approach (Rappuoli, 2000) which initiates a huge move in the development of vaccine against the deadly pathogens. The strategy included the comprehensive utilization of bioinformatics algorithm or tools to develop epitope based vaccine molecules, though further validation and experimental procedures are also needed (Moxon et al., 2019) . In addition, peptide based subunit vaccines are biologically safer due to the absence of continuous in vitro culture during the production period, and also implies an appropriate activation of immune responses (Purcell et al., 2007; Dudek et al., 2010) . Such immunoinformatic approaches have already been employed by the researchers to design vaccines against a number of deadly pathogens including Ebola virus (Khan et al., 2015) , HIV (Pandey et al., 2018) , Areanaviruses , Marburgvirus , Norwalk virus (Azim et al., 2019b) , Nipah virus (Saha et al., 2017) , influenza virus (Hasan et al., 2019b) and so on. At present, a suitable peptide vaccine to combat COVID-19 is urgently necessary that could efficiently generate enough immune response to destroy the virus. Hence, the study was designed to develop a chimeric recombinant vaccine against SARS-CoV-2 by targeting four major structural proteins of the pathogen, while revealing the evolutionary history of different 'nucleotide'. A total 61 complete genomes were retrieved, with unique identity (Supplementary File 1). Protein sequence of the spike, envelope, membrane and nucleocapsid were also retrieved from the corresponding genome sequences found in NCBI (Supplementary File 1).

The complete genome sequences of coronaviruses and the proteins of envelope, envelope, membrane and nucleocapsid were employed to construct different phylogenetic trees. Multiple sequence alignment (MSA) of the complete genome and protein sequences were performed using MAFFT v7.310 (Katoh and Standley, 2013) tool. For the whole genome alignment, we used MAFFT Auto algorithm, while for the protein sequences alignment, MAFFT G-INS-I algorithm was used using default parameters. Next, alignment was visualized using the JalView-2.11 (Waterhouse et al., 2009) . Alignment position with more than 50% gaps was pruned from coronavirus genome using Phyutility 2.2.6 program (Smith and Dunn, 2008) . Again, more than 20% gaps from the spike protein alignment were removed. PartitionFinder-2.1.1 (Lanfear et al., 2017) indicated the best fit substitution model of the completed genome sequences and the protein sequences. The phylogeny of the whole genome sequences of coronavirus was constructed using both the Maximum Likelihood Method and Bayesian Method. RAxML version 8.2.11 (Stamatakis, 2014 ) with the substitution model GTRGAMMAI was used using 1000 rapid bootstrap replicates. MrBayes version 3.2.6 (Ronquist et al., 2012) with INVGAMMA model was used for the corona virus genomes. Phylogenetic analyses of four different protein sequences were performed by using RAxML-8.2.11 tool. For spike and nucleocapsid proteins, we found PROTGAMMAIWAG and PROTGAMMAIWAG as the best fit model, respectively.

Again, PROTGAMMAWAG was the best fit model of evolution for both the membrane and envelope proteins. For the retrieval of the domain sequences of the stated protein sequences, In the present study, reverse vaccinology technique was utilized to model a novel multiepitope subunit vaccine against 2019-nCoV. The scheme in Figure 1 represents the complete methodology that has been adopted to develop the final vaccine construct. Among 496 proteins (available in the NCBI database) from different strains of novel corona virus, four structural proteins, i.e. spike glycoprotein, membrane glycoprotein, envelope protein and nucleocapsid protein, were prioritized for further investigation (Supplementary File 2). After sequence retrieval from NCBI, the sequences were subjected to BLASTp analysis to find out the homologous protein sequences. Multiple sequence alignment was done by using Clustal Omega to identify the conserved regions (Sievers and Higgins, 2014) .The topology of each conserved regions were predicted by TMHMM Server v.2.0 (http://www.cbs.dtu.dk/services/TMHMM/), while the antigenicity of the conserved regions was determined by VaxiJen v2.0 (Doytchinova and Flower, 2007a).

Only the common fragments were used for T-Cell epitopes enumeration via T-Cell epitope prediction server of IEDB (http://tools.iedb.org/main/tcell/) (Vita et al., 2014) . Again, TMHMM server was utilized for the prediction of transmembrane topology of predicted MHC-I and MHC-II binding peptides followed by antigenicity scoring via VaxiJen v2.0 server (Krogh et al., 2001; Doytchinova and Flower, 2007b) . The epitopes which have antigenic potency were picked and used for preceding analysis.

The level of conservancy scrutinizes the ability of epitope candidates to impart capacious spectrum immunity. Homologous sequence sets of the chosen antigenic proteins were retrieved from the NCBI database by utilizing BLASTp tool. Later, conservancy analysis tool (http://tools.iedb.org/conservancy/) in IEDB was used to demonstrate the conservancy level of the predicted epitopes among different viral starins. The toxicity of non-allergenic epitopes was enumerated by using ToxinPred server (Gupta et al., 2013) . J o u r n a l P r e -p r o o f Journal Pre-proof

Among different ethnic societies and geographic spaces, the HLA distribution varies around the world. Population coverage study was conducted by using IEDB population coverage calculation server (Vita et al., 2014) . To check the allergenicity of the proposed epitopes, four distinct servers i.e. AllergenFP (Dimitrov et al., 2014) , AllerTOP (Dimitrov et al., 2013) , Allermatch (Fiers et al., and Allergen Online (http://www.allergenonline.org/) servers were utilized.

Three different algorithms i.e. Bepipred Linear Epitope Prediction 2.0 (Jespersen et al., 2017) , Emini surface accessibility prediction (Emini et al., 1985) and Kolaskar and Tongaonkar antigenicity scale (Kolaskar and Tongaonkar, 1990) from IEDB predicted the potential B-Cell epitopes within conserved fragments of the chosen viral proteins. To cross check the epitope conservancy, we used 30 strains from 30 different countries using World Health Organization's most infected countries' list. We demonstrated the conservancy for both B-cell and T-cell epitopes used to design the final vaccine construct in this study.

Top CTL, HTL and B cell epitopes were compiled to design the final vaccine constructs in the study. Each vaccine constructs commenced with an adjuvant followed by top CTL epitopes, HTL epitopes and BCL epitopes respectively. For construction of novel corona vaccine, the chosen adjuvants i.e. L7/L12 ribosomal protein, beta defensin (a 45 mer peptide) and HABA protein (M. tuberculosis, accession number: AGV15514.1) were used (Rana and Akhter, 2016) .

Several linkers such as EAAAK, GGGS, GPGPG and KK in association with PADRE sequence were incorporated to construct fruitful vaccine sequences against COVID-19. The constructed vaccines were then analyzed whether they are non-allergenic by utilizing the following tool named Algpred (Azim et al., 2019) . The most potential vaccine among the three constructs was then determined by assessing the antigenicity and solubility of the vaccines via VaxiJen v2.0 (Doytchinova and Flower, 2007b) and Proso II server (Smialowski et al., 2006) , respectively. J o u r n a l P r e -p r o o f Journal Pre-proof

ProtParam tool (https://web.expasy.org/protparam/), provided by ExPASy server (Hasan et al., 2019c ) was used to functionally characterize (Gasteiger et al., 2003) the vaccine constructs. The studied functional properties were isoelectric pH, molecular weight, aliphatic index, instability index, hydropathicity, estimated half-life, GRAVY values and other physicochemical characteristics. Alpha helix, beta sheet and coil structures of the vaccine constructs were analyzed through GOR4 secondary structure prediction method using Prabi (https://npsaprabi.ibcp.fr/). In addition, Espript 3.0 (Robert and Gouet, 2014) was also used to predict the secondary structure of the stated protein sequences.

Vaccine 3D model was generated on the basis of percentage similarity between target protein and available template structures from PDB by using I-TASSER (Peng and Xu, 2011) . The modeled structures were further refined via FG-MD refinement server. Structure validation was performed by Ramachandran plot assessment in RAMPAGE (Hasan et al., 2019b) . By utilizing DbD2 server, probable disulfide bonds were designed for the anticipated vaccine constructs (Craig and Dombkowski, 2013) . The value of energy was considered < 2.5, while the chi3 value for the residue screening was chosen between -87 to +97 for the operation (Hasan et al., 2019b) .

The B-cell epitopes of putative vaccine molecules were predicted via ElliPro server (http://tools.iedb.org/ellipro/) with minimum score 0.5 and maximum distance of 7 Å (Ponomarenko et al., 2004) . Moreover, IFN-inducing epitopes within the vaccine were predicted using IFNepitope with motif and SVM hybrid detection strategy (Hajighahramani et al., 2017) .

J o u r n a l P r e -p r o o f Journal Pre-proof Normal mode analysis (NMA) was performed to predict the stability and large scale mobility of the vaccine protein. The iMod server determined the stability of construct V3 by comparing the essential dynamics to the normal modes of protein (Aalten et al, 1997; Wuthrich et al., 1980) . It is a recommended alternative to costly atomistic simulation (Tama and Brooks, 2006; Cui and Bahar, 2007) and shows much quicker and efficient assessments than the typical molecular dynamics (MD) simulations tools (Prabhakar et al., 2016; Awan et al., 2017) . The main-chain deformability was also predicted by measuring the efficacy of target molecule to deform at each of its residues. The motion stiffness was represented via eigenvalue, while the covariance matrix and elastic network model was also analyzed.

Patchdock server was prioritized for docking between different HLA alleles and the putative vaccine molecules (Azim et al., 2020) . In addition, the superior construct was also docked with different human immune receptors such as ACE 3, APN, DPP4 and TLR-8. The 3D structures of these receptors were retrieved from RCSB protein data bank. Detection of highest binding affinity between the putative vaccine molecules and the receptor was experimented based on the lowest interaction energy of the docked structure.

JCAT tool was utilized for codon adaptation in order to fasten the expression of vaccine construct V3 in E. coli strain K12. For this, some restriction enzymes (i.e. BglI and BglII), Rho independent transcription termination and prokaryote ribosome-binding site were put away from the work (Grote et al., 2005) . After that, the mRNA sequence of constructed V3 vaccine was ligated within BglI (401) and BglII (2187) restriction site at the C-terminal and N-terminal sites respectively. SnapGene tool was utilized for in silico restriction cloning (Solanki and Tiwari, 2018) .

J o u r n a l P r e -p r o o f Journal Pre-proof

In the phylogenetic analysis, we introduced different coronavirus from three different genera: alpha-coronavirus, beta-coronavirus and gamma-coronavirus. Total 61 species of the corona virus covered 21 sub-genera (Supplementary Table 1 and Figure 2 ). These 61 species of corona viruses included 7 pathogenic species (Figure 2 ), which are: COVID-19 or SARS-CoV-2, SARS-CoV-1 virus, MERS virus, HCoV-HKU1, HCoV-OC43, HCoV-NL63, HCoV-229E (Forni et al., 2017; Zumla et al., 2016) . Among these, the first five species belong to the beta-coronavirus genera, while the last two belongs to the alpha-genera. Here, none of the members of Gammacoronavirus studied in this study were found to use human as potential host.

Apart from the human coronaviruses, we introduced other coronaviruses which choose different species of bats, whale, turkey, rat, mink, ferret, swine, camel, rabbit, cow and others as host (Supplementary Table- 

The phylogeny of these species clearly revealed two broad clades (Figure 2) , where first large clade contains Gammacoronavirus and Alpha-coronavirus genera, while the other belongs to the beta-coronavirus. Within the beta-coronavirus clade, we found three clear divisions.

HCoV-HKU1 and HCoV-OC43 have been placed in the first clade, while in the second clade we found MERS coronavirus. COVID-19 or SARS-COV-2 formed clade with SARS-COV-1 and bat beta-coronaviruses (Figure 2 ), which is consistent with the previous finding (Ceraolo and Giorgi, 2020) . Though SARS-CoV-1 belongs to the same sub-genus as the COVID-19, the bat coronaviruses belong to two different sub-genera including Hibecovirus and Nobecovirus (Supplementary File 1).

Domain analysis of spike protein of coronaviruses reveals that they contain mainly one signature domains namely, coronavirus S2 glycoprotein (IPR002552), which is present in all the candidates. All other beta-coronavirus contains spike receptor binding protein (IPR018548), coronavirus spike glycoprotein hapted receptor 2 domain (IPR027400) and spike receptor binding domain superfamily (IPR036326). SARS-CoV-1 contains an extra domain, namely spike glycoprotein N-terminal domain (IPR032500), which is also present in some the sub-genera (Embecovirus) of beta-coronavirus, but not in COVID-19. One important finding in our study is J o u r n a l P r e -p r o o f that the COVID-19 candidates do not contain the domain spike glycoprotein (IPR042578), which is present in the SARS-CoV-1 ( Figure 3 ). The secondary structure prediction study shows a large numbers of cysteine residues which contribute to the formation of disulfide bonds within the spike protein. Most of them fall within the S1 spike protein, which is 654 amino acid long in SARS-CoV-1, while 672 amino acids long in COVID-19. The RGD motif which is conserved within the COVID-19 is present in the vicinity of the S1 protein. It exists as KGD that clearly demonstrates the mutation over the short time period. Again, the receptor binding domain and receptor binding motif analyses disclose variations within several region between the COVID19 and SARS-CoV-1 (Supplementary File 2). The domain-based phylogenetic analysis reflects two main divisions, where the all the novel beta-coronavirus i.e., COVID19 form clade with the SARS-CoV-1; while other beta-coronavirus fall in another clade which further divide to give rise different sub-genera. This clearly shows that the COVID-19 exerts specific ancestral connection to the SARS-CoV-1 in terms of spike glycoproteins. Interestingly, our study also revealed close relatedness of both the SARS-CoV-1 and COVID-19 to the bat beta-coronavirus that belongs to the Hibecovirus sub-genus. However, in our study, the bat coronaviruses of Nobecovirus subgenus did not fall into the same clade of novel coronaviruses. The phylogenetic study and MSA also revealed that, the functional portion of the spike glycoprotein domain and spike glycoprotein N-terminal domain might be lost from the COVID-19 during the course of evolution.

The envelope proteins of both beta-coronavirus and Alpha-coronavirus contain only one protein domain (IPR003873) namely, Nonstructural protein NS3 or small envelope protein E (NS3/E).

This domain is well conserved in coronavirus and also found in murine hepatitis virus. On the other hands, the gamma coronavirus shows the exception, which possess (IPR005296) IBV3C protein domain, which thought to be expressed from the ORF3C gene of infectious bronchitis virus (Jia and Naqi, 1997) (Surya et al., 2015) . Unlike to earlier finding, we got that gamma-coronavirus candidate in our study shows close connection with both SARS-CoV-1 and COVID-19 in terms of envelope proteins. 

The length of nucleocapsid proteins of beta-coronavirus genus ranges from 410 to 450 amino acids. Three signature domains are mainly present in the nucleocapsid proteins, which are:

Coronavirus Nucleocapsid protein (IPR001218), Nucleocapsid Proteins C-terminal (IPR037179) and Nucleocapsid Proteins N-terminal (IPR037195). However, in our experiment, we didn't find these domains in HCoV-HKU1 ( Figure 6 ); this virus belongs to Embecovirus sub-genus and contains only Coronavirus Nucleocapsid I (IPR004876) domain. The candidates of alpha-and gamma-coronavirus have their special domains. According to our domain-based phylogeny study of nucleocapsid proteins, we found the close approximation of the COVID-19 with the SARS-CoV-1, which is consistent with the findings of phylogeny of whole genome. Strikingly, unlike spike and membrane proteins, the closest homologs of COVID-19 are not only the SARS-COV-1 and bat coronaviruses (Sub-genus: Hibecovirus and Nobecovirus), but it also includes the MERS viruses and other proteins which is from the Merbecovirus sub-genus.

A total 31, 24, 29 and 29 sequences of spike glycoprotein, membrane glycoprotein, envelope protein and nucleocapsid protein were retrieved from the NCBI database belonging to different strains of SARS-CoV-2. Following by BLASTp analysis and Multiple Sequence Alignment, two conserved regions were detected for membrane glycoprotein and nucleocapsid, while single fragments were identified for both spike glycoprotein and envelope protein (Table 1) .Results showed that, all the conserved sequences except one from membrane glycoprotein met the criteria of default threshold standard in VaxiJen. Again, transmembrane topology scrutinizing showed that among the immunogenic conserved sequences from the corresponding proteins except spike glycoprotein met the criteria of desired exomembrane characteristics (Table 1) .

J o u r n a l P r e -p r o o f A plethora of immunogenic epitopes were generated from the conserved sequences that were able to bind with most noteworthy number of HLA cells (Supplementary Table 1, Supplementary   Table 2, Supplementary Table 3 and Supplementary Table 4 ). Top epitopes with exomembrane characteristics were ranked for each individual protein after investigating their antigenicity score and transmembrane topology (Table 2) .

Epitopes from each protein showed high level of conservancy up to 100% (Table 2 ). ToxinPred server predicted the relative toxicity of each epitope which indicated that the top epitopes were non-toxin in nature (Supplementary Table 5 ). Population coverage of four structures proteins were also done for the predicted CTL and HTL epitopes. From the screening, results showed that population of the various geographic regions could be covered by the predicted T-cell epitopes ( Figure 7) .Finally, the allergenic epitopes were excluded from the list based on the evaluation of four allergenicity prediction server (Supplementary Table 5 ).

Top B-cell epitopes were predicted for Spike glycoprotein, membrane glycoprotein, envelope protein and nucleocapsid protein using 3 distinct algorithms (i.e. Bepipred Linear Epitope prediction, Emini Surface Accessibility, Kolaskar and Tongaonkar Antigenicity prediction) from IEDB. Epitopes were also allowed to analyze their vaxijen scoring and allergenicity (Table 3) .

Results revealed that top B-cell and T-cell epitopes were highly conserved (up to100%) among different strains of SARS-CoV-2 (Table 4 ), while 19 out of final 20 epitopes showed conservancy >90%. Therefore, the designed vaccine construct is expected to confer broad range immunity in the host. Table 6 ). PADRE sequence was included to extend the efficacy and potency of the constructed vaccine. The putative vaccine constructs, V1, V2 and V3 were 397, 481 and 510 residues long respectively. However, allergenicity score of V3 (-0.89886723) revealed that it was superior among the three constructs in terms safety and efficacy. V3 also had a solubility score (0.60) ( Figure 8E ) and antigenicity (0.58) over threshold value (Table 5) .

ProtParam tool was employed to analyze the physicochemical properties of V3. Molecular weight of 3 was scored as 55.181 kDa. The extinction coefficient of V3 was calculated as 63830 at 0.1% absorption. It had been found that the protein would have net negative charge which was higher than the recommended pI 9.81. Aliphatic index and GRAVY value were found 77.80 and -0.383 respectively, which could express the thermostability and hydrophilic status of the V3 vaccine construct. Around sixty minutes in vitro half-life stability in mammalian reticulocytes was predicted for V3. The computed instability index (II) 36.98 classified the protein as a stable one. In contrast, Secondary structure of V3 exhibited to have 46.47% alpha helix, 15.00% sheet and 38.63% coil structure (Supplementary Figure 1) .

Tertiary structure of the putative vaccine construct V3 was generated using I-TASSER server ( Figure 8A and 8B). The server used 10 best templates with highest significant (measured via Zscore) from the LOMETS threading program to model the 3D structure. After refinement, Ramachandran plot analysis revealed that 92.7% and 5.7% residues were in the favored and allowed regions respectively, while only 8 residues (1.6%) occupied in the outlier region ( Figure 8C) . The overall quality factor determined by ERRAT server was 91.56% ( Figure 8D Figure 3) .

Ellipro server predicted a total 6 conformational B-cell epitopes from the 3D structure of the construct V3. Epitopes No. 1 were considered as the broadest conformational B cell epitopes with 25 amino acid residues (Figure 9 and Supplementary Table 7 ). Results also revealed that Table 8 ).

Stability of the vaccine construct V3 was investigated through mobility analysis ( Figure 10A and 10B), B-factor, eigenvalue and deformability analysis, covariance map and recommended elastic network model. Results revealed that the placements of hinges in the chain was insignificant ( Figure 10C ) and the B-factor column gave an averaged RMS ( Figure 10D ). The estimated higher eigenvalue 6.341333e -06 ( Figure 10E ) indicated low chance of deformation of vaccine protein V3. The correlation matrix and elasticity of the construct have been shown in Figure 10G and Figure 10H , respectively.

The structural interaction between HLA alleles and the designed vaccines were investigated by molecular docking approach. The server detected the complexed structure by focusing on complementary score, ACE (Atomic Contact Energy) and estimated interface area of the compound (Table 6 ). The molecular affinity between the putative vaccine molecules V3 and several immune receptors were also experimented. The result showed that construct V3 interacted with each receptor with significantly lower binding energy (Figure 11 ). J o u r n a l P r e -p r o o f

The Codon Adaptation Index (CAI) and GC content for the predicted codons of the putative vaccine constructs V1 were demonstrated as 1.0 and 51.56% respectively. An insert of 1542 bp was found which lacked the restriction sites for BglI and BglII, thus providing comfort zone for cloning. The codons were inserted into pET28a(+) vector alongside two restriction sites (BglI and BglII) and a clone of 5125 base pair was generated (Figure 12 ).

In December 2019, a new coronavirus prevalence flourished in Wuhan, China, causing clutter among the medical community, as well as to the rest of the world . The new species has been renamed as 2019-nCoV or, SARS-CoV-2, already causing considerable number infections and deaths in China, Italy, Spain, Iran, USA and to a growing degree throughout the world. The major outbreak and spread of SARS-CoV-2 in 2020 forced the scientific community to make considerable investment and research activity for developing a vaccine against the pathogen. However, owing to high infectivity andpathogenicity, the culture of SARS-CoV-2 needs biosafety level 3 conditions, which may obstructed the rapid development of any vaccine or therapeutics. It had been found that about 35 companies and academic institutions are engaged in such works (Spinney et al., 2020 , Ziady et al., 2020 . Among the potential SARS-CoV-2 vaccines in the pipeline, four have nucleic acid based designs, four involve nonreplicating viruses or protein constructs, two contain live attenuated virus and one involves a viral vector (Pang et al., 2020) , while only one, called mRNA-1273 (developed by NIAID collaboration with Moderna, Inc.), has confirmed to start phase-1 trial (NIH, 2020). However, in this study we emphasized on a different approaches by prioritizing the advantages of different genome and proteome database using the immunoinformatic approach. Computational vaccine predictions were adopted by the researchers to design vaccines against both MERS-CoV (Sudhakar et al., 2013; Fernando et al., 2013) and SARS-CoV-1 (Yang et al., 2003; Oany et al., 2014) , targeting the outer membrane or functional proteins (Sharmin and Islam, 2014) . Several in silico strategies have also been employed to predict potential T cell and B cell epitopes against SARS-CoV-2, either emphasizing on spike glycoprotein or envelope proteins (Behbahani, 2020;  J o u r n a l P r e -p r o o f Rasheed et al., 2020) . None of the studies, however, focused on other structural proteins.

Moreover, random genetic changes and mutations in the protein sequences (Yin, 2020) may obstruct the development of effective vaccines and therapeutics against human coronavirus in the future. Hence, the present study was employed to identify the similarity and divergence among the close relatives of the target pathogen and develop a novel chimeric recombinant vaccine considering all major structural proteins i.e. spike glycoprotein, membrane glycoprotein, envelope protein and nucleocapsid protein simultaneously.

Structural proteins are often chosen as attractive therapeutic targets by the researchers due to their surface exposure. Spike (S) protein is currently the most promising antigen formulation for SARS-CoV-2 vaccine research which is able to be directly recognized by host immune system (Wrapp et al., 2020) and already been used for vaccine development to prevent Severe Acute Respiratory Syndrome (SARS) and Middle-East Respiratory Syndrome (MERS) (Zhou et al., 2018; Du et al., 2009 ). However, Membrane (M) protein, the most abundant one on the virus surface (Neuman et al., 2011) , was also reported to stimulate efficient neutralizing antibodies in SARS patients upon immunization (Pang et al., 2004) . Moreover, structural investigation revealed the existence of T-cell epitope cluster on the trans-membrane domain of M protein with the ability to induce a strong cellular immune response (Liu et al., 2010) . Thus, it can be utilized as a candidate antigen for developing SARS-CoV-2 vaccine. Researchers have already considered Envelope (E) protein for vaccine candidacy against COVID-19 due to high antigenicity (Abdelmageed et al., 2020). It was also investigated against SARS-CoV in 2003 and more recently, against MERS-CoV (Schoeman and Fielding, 2019). Nucleocapsid (N) protein, on the other hand, is believed to be more conserved than spike or membrane glycoprotein with the potential to elicit broad-based cellular responses (Zhao et al., 2005) . Previously, cellular response against the N protein of some animal coronaviruses enhanced recovery from viral infection (Glansbeek et al., 2002; Wasmoen et al., 1995; Wesseling et al., 1993) . A study showed that N protein of SARS-CoV act as an important B cell immunogen, indicating its potential value in vaccine development against SARS (Zhao et al., 2005) . All these data suggest that S, E, M and N protein can induce both humoral and cellular immune responses against SARS-CoV-2.

Phylogenetic analysis is used for fundamental as well as applied issues of virus research and it includes the development of antiviral drugs and vaccines (Gorbalenya and Lauber, 2017) .

Here, we used phylogeny data to perform similarity analysis between different coronavirus subfamiles to finalize which structural protein to be used as vaccine target in this study. We wanted to target the proteins which are most common in each subfamily and exhibit significant similarities to design a broad and universally effective vaccine candidate. The results revealed that each of the four major structural proteins possess highly conserved domains among alpha-, beta-and gamma-coronaviruses. Therefore we considered all major structural proteins to design a multiepitope subunit vaccine which is expected to stimulate more effective and broad response in the host. The topology of the phylogenetic trees of the whole genome and the stated four proteins sequences from different species of coronaviruses reveal that SARS-CoV-1 and bat coronaviruses are the closest homologs of the novel coronaviruses. Our results infer a significant level of similarities within the COVID-19 and SARS-CoV-1 which was also aligned with the previous findings (Jaimes et al., 2020; Wu, 2020a) . The sequence similarities between the SARS-CoV, bat coronaviruses and the COVID-19 from the reported studies (Hu et al., 2018; Wu et al., 2020; Wu, 2020b) suggests that those are distantly related, in spite those are capable of infecting the humans and therefore possess the adaptive convergent evolution.

Interestingly, the COVID-19 envelope proteins form clade with the Turkey coronavirus which belongs to gamma-coronavirus genus. So, in terms of envelope proteins, the envelope gene of turkey coronavirus might contribute to the convergence process, which needs further analysis. In addition, from the domain-based phylogeny of nucleocapsid proteins, it can be deduced that this protein might have originated in bats and was transmitted to camels and then later on choose human as the potential host. Overall, the COVID-19 might go through complex adaptation strategies in order to be transmitted into the human via different animals.

The homologous protein sets for four structural proteins of Coronavirus were sorted to identify conserved regions through BLASTp analysis and MSA. Only the conserved sequences were utilized to identify potential B-cell and T-cell epitopes for each individual protein (Table   1) . Thus, our constructs are expected to stimulate a broad-spectrum immunity in host upon administration. Cytotoxic CD8+T lymphocytes (CTL) play a crucial role to control the spread of pathogens by recognizing and killing diseased cells or by means of antiviral cytokine secretion (Garcia et al., 1999) . Thus, T cell epitope-based vaccination is a unique process to confer defensive response against pathogenic candidates (Shrestha, 2004) . Approximately 800 MHC-I peptides (CTL epitopes) and 600 MHC-II peptides (HTL epitopes) were predicted via IEDB J o u r n a l P r e -p r o o f server, from which we screened the top ones through analyzing the antigenicity score, transmembrane topology, conservancy level and other important physiochemical parameters employing a number of bioinformatics tools ( Table 2 ). The top 10 epitopes from each protein was further assessed by investigating the toxicity profile and allergenicity pattern. Different servers rely on different parameters to predict the allergenic nature of small peptides. Therefore, we used 4 distinct servers for such assessment and the epitopes predicted as non-allergen at least via 3 servers were retained for further analysis (Supplementary Table 5 ). Vaccine initiates the generation of effective antibodies that are usually produced by B cells and plays effector functions by targeting specifically to a foreign particles (Cooper and Nemerow, 1984) . The potential B cell epitopes were generated by three different algorithms (Bepipred linear epitope prediction 2.0, Kolaskar and Tongaonkar antigenicity prediction and Emini surface accessibility prediction) from IEDB database (Table 3) .

Suitable linkers and adjuvants were used to combine top finalized epitopes from each protein that led to develop multiepitope vaccine molecules (Supplementary Table 6 ). As PADRE sequence was usually recommended to lessen the polymorphism of HLA molecules in the population (Ghaffari-Nazari et al., 2015) , it was also considered to construct the final vaccine molecule. Here, adjuvants would enhance the immunogenicity of the vaccine constructs and appropriate separation of epitopes in the host environment would be ensured by the linker (Yang et al., 2015) . Allergenicity, physiochemical properties, antigenicity and three-dimensional structure of vaccine constructs were characterized, and it was concluded that V3 was superior to V1 and V2 vaccine constructs due to its highly negative allergenicity score (-0.89886723).

Therefore, it is expected to be less likely to cause adverse side effects or hypersensitivity. V3 also had a solubility score (0.60) and antigenicity (0.58) over threshold value (Table 5) . Hence, construct V3 was proposed as the most suitable and safe vaccine protein for further analysis.

The final construct also occupied by several interferon-α producing epitopes (Supplementary Table 8 ). The vaccine protein (V3) was subjected to di-sulfide engineering to enhance its stability. Analysis of the normal modes in internal coordinates by iMODS was employed to investigate the collective motion of vaccine molecules (Lopez-Blanco et al., 2014) .

Negligible chance of deformability at molecular level was analyzed for the putative vaccine construct V3, thereby strengthening our prediction. Moreover, molecular docking was J o u r n a l P r e -p r o o f investigated to analyze the molecular affinity of the vaccine with different HLA molecules i.e. DRB1*0101, DRB5*0101, DRB3*0202, DRB1*0401, DRB3*0101 and DRB1*0301 (Table 6) .

It had been reported that a specific receptor-binding domain of CoV spike protein usually recognizes its host receptor ACE2 (angiotensin-converting enzyme 2) (Li. et al., 2003; Li, 2015) .

Previous studies also identified dipeptidyl peptidase 4 (DPP4) as a functional receptor for human coronavirus (Raj et al., 2013) . Therefore, we performed another docking study prioritizing these immune receptors to strengthen our prediction (Figure 11 ). Results showed that the designed construct bound with the selected receptors with minimum binding energy which was biologically significant. Finally, in-silico restriction cloning was adopted to check the suitability of construct V3 for entry into pET28a (+) vector and expression in E. coli strain K12 (Figure 12 ).

Traditional ways to vaccine development are time consuming and laborious. Moreover, the result may not be always as expected or fruitful (Stratton et al., 2003; Hasan et al., 2019) . In silico prediction and prescreening methods, on the contrary, offer some advantageswhile saving time and cost for production. Therefore, the present study may aid in the development of preventive strategies and novel vaccines to combat infections caused by 2019-nCoV. However, further wet lab trials involving model organism needs to be experimented for validating our findings. J o u r n a l P r e -p r o o f Table 6 : Docking score of vaccine construct V3 with different HLA alleles and human immune receptors The darker the greys, the stiffer the springs (H). 

Screening and druggability analysis of some plant metabolites against SARS-CoV-2: An integrative computational approach. Informatics in Medicine Unlocked

Immunoinformatics approaches for designing a novel multi epitope peptide vaccine against human norovirus (Norwalk virus). Infection, Genetics and Evolution

Conglomeration of highly antigenic nucleoproteins to inaugurate a heterosubtypic next generation vaccine candidate against Arenaviridae family. bioRxiv

In silico Design of novel Multi-epitope recombinant Vaccine based on Coronavirus Spike glycoprotein

Genomic variance of the 2019-nCoV coronavirus

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Pathogenicity and transmissibility of 2019-ncov-a quick overview and comparison with other emerging viruses

The role of antibody and complement in the control of viral infections

Disulfide by Design 2.0: a web-based tool for disulfide engineering in proteins

normal mode analysis theoretical and applications to biological and chemical systems

Protein identification and analysis tools on the ExPASy server. InThe proteomics protocols handbook

Improving multi-epitope long peptide vaccine potency by using a strategy that enhances CD4+ T help in BALB/c mice

Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus

Phylogeny of viruses. Reference Module in Biomedical Sciences

A decade after SARS: strategies for controlling emerging coronaviruses

JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic acids research

Clinical characteristics of coronavirus disease 2019 in China

In Silico Approach for Predicting Toxicity of Peptides and Proteins

Vaccinomics strategy for developing a unique multi-epitope monovalent vaccine against Marburg marburgvirus. Infection, Genetics and Evolution

Reverse vaccinology approach to design a novel multi-epitope subunit vaccine against avian influenza A (H7N9) virus

Contriving a chimeric polyvalent vaccine to prevent infections caused by Herpes Simplex Virus (Type-1 and Type-2): an exploratory immunoinformatic approach

Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats. Emerging microbes and infections

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan

Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses

Chinese scientists race to develop vaccine as coronavirus death toll jumps". South China Morning Post

BepiPred-2.0: Improving sequence-based B-cell epitope prediction using conformational epitopes

Sequence analysis of gene 3, gene 4 and gene 5 of avian infectious bronchitis virus strain CU-T2

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. The Journal of infectious diseases

iMODS: internal coordinates normal mode analysis server

Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle

Editorial: Reverse Vaccinology. Frontiers in Immunology

A structural analysis of M protein in coronavirus assembly and morphology

Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein

NIH clinical trial of investigational vaccine for COVID-19 begins. Study enrolling Seattle-based healthy adult volunteers

Design of an epitope-based peptide vaccine against spike protein of human coronavirus: an in silico approach. Drug Design

Immunoinformatics approaches to design a novel multi-epitope subunit vaccine against HIV infection. Vaccine

Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine

Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review

Exploiting structure information for protein alignment by statistical inference

Vaccine adjuvants: current state and future trends

Monomerization alters the dynamics 897 of the lid region in campylobacter jejuniCstII: an MD simulation study

More than one reason to rethink the use of peptides in vaccine design

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

In silico identification of novel B cell and T cell epitopes of Wuhan coronavirus (2019-nCoV) for effective multi

Deciphering key features in protein structures with the new ENDscript server

MrBayes 3.2: efficient Bayesian phylogenetic inference and model choice across a large model space

In silico identification and characterization of common epitope-based peptide vaccine for Nipah and Hendra viruses. Asian Pacific journal of tropical medicine

Coronavirus envelope protein: current knowledge. Virology journal

A highly conserved WDYPKCDRA epitope in the RNA directed RNA polymerase of human coronaviruses can be used as epitope-based universal vaccine design

Role of CD8+ T cells in control of West Nile virus infection

Clustal omega, accurate alignment of very large numbers of sequences

Protein solubility: sequence based prediction and experimental verification

Phyutility: A phyloinformatics tool for trees, alignments and molecular data

Subtractive proteomics to identify novel drug targets and reverse vaccinology for the development of chimeric vaccine against Acinetobacter baumannii

When will a coronavirus vaccine be ready?". The Guardian. Retrieved

RAxML version 8: A tool for phylogenetic analysis and post-analysis of large phylogenies

Immunization safety review: vaccinations and sudden unexpected death in infancy, Institute of Medicine (US)

Platform strategies for rapid response against emerging coronaviruses: MERS-CoV serologic and antigenic relationships in vaccine design

COVID-19: epidemiology, evolution, and cross-disciplinary perspectives

Potential factors influencing repeated SARS outbreaks in China

MERS coronavirus envelope protein has a single transmembrane domain that forms pentameric ion channels

Symmetry, form, and shape: guiding principles for robustness in macromolecular machines

Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of

Cytokines: the future of intranasal vaccine adjuvants. Clinical and Developmental Immunology

The immune epitope database (IEDB) 3.0. Nucleic acids research

A novel coronavirus outbreak of global health concern. The Lancet

Protection of cats from infectious peritonitis by vaccination with a recombinant raccoon poxvirus expressing the nucleocapsid gene of feline infectious peritonitis virus

Jalview Version 2-A multiple sequence alignment editor and analysis workbench

Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection

World Health Organization. Coronavirus disease (COVID-19) outbreak

World Health Organization. Infection prevention and control during health care when COVID-19 is suspected: interim guidance

disease in China

Strong evolutionary convergence of receptor-binding protein spike between COVID-19 and SARS-related coronaviruses

Strong evolutionary convergence of receptor-binding protein spike between COVID-19 and SARS-related coronaviruses

Correlations between internal mobility and stability of globular proteins

An evolutionary RGD motif in the spike protein of SARS-CoV-2 may serve as a potential high risk factor for virus infection

In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

Genotyping coronavirus SARS-CoV-2: methods and implications

Atomic-level protein structure refinement using 857 fragmentguided molecular dynamics conformation sampling

Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Prospects for a MERS-CoV spike vaccine. Expert review of vaccines

A novel coronavirus from patients with pneumonia in China

Biotech companyModerna says its coronavirus vaccine is ready for first tests

Coronaviruses-drug discovery and therapeutic options